IL6 and lung cancer: In addition, it has been shown in mouse models that this bacterium may support the response to cisplatin-based chemotherapy in lung cancer patients, downregulating the levels of ki-67 (marker of proliferation), p53 (tumor protein 53), and FasL (Fas cell surface death receptor ligand) proteins and upregulating Fas (Fas Cell Surface Death Receptor) proteins, inducing the proinflammatory factors levels such as IFN-γ (Interferon-γ), IL-6 (Interleukin 6), and TNF-α (Tumor Necrosis Factor α) (Chen et al. 2020).